Last updated: July 31, 2026
Torsemide is a generic loop diuretic used for edema associated with heart failure, renal disease and hepatic disease, and for hypertension. Its commercial market is mature, price-driven and exposed to substitution by furosemide. The most important recent evidence, the randomized TRANSFORM-HF trial, found no mortality advantage for torsemide over furosemide after hospitalization for heart failure. Torsemide retains clinical value through predictable oral absorption, longer duration of action and potential use in patients with variable furosemide response, but those attributes have not produced a major branded market.
What is the current FDA status of torsemide?
Torsemide is FDA-approved as an immediate-release oral tablet and is available in generic products and the branded product Soaanz. Earlier U.S. branding included Demadex.
| Regulatory attribute |
Torsemide status |
| Active ingredient |
Torsemide, also known as torsemide |
| Drug class |
Loop diuretic |
| FDA route |
Oral |
| Main dosage forms |
Tablets |
| Approved uses |
Edema associated with heart failure, renal disease and hepatic disease; hypertension |
| Reference branded product |
Demadex |
| Current branded product |
Soaanz |
| Generic availability |
Extensive |
| U.S. regulatory pathway |
Abbreviated New Drug Application, or ANDA, for generics |
| Biologic or biosimilar status |
Not applicable |
| Controlled substance status |
Not controlled |
| Prescription status |
Prescription-only |
The FDA labeling describes torsemide tablets in strengths including 5 mg, 10 mg, 20 mg and 100 mg, depending on the product. The drug is administered once daily in most approved uses. Dosing differs by indication and patient factors, particularly renal function, hepatic disease and degree of volume overload (FDA, 2024a; DailyMed, 2024).
What clinical trials have evaluated torsemide versus furosemide?
What did the TRANSFORM-HF trial show?
TRANSFORM-HF was the largest modern randomized comparison of torsemide and furosemide in patients hospitalized with heart failure. The trial enrolled 2,859 patients across 60 U.S. hospitals and followed them for a median of 17.4 months.
| TRANSFORM-HF result |
Torsemide |
Furosemide |
| All-cause mortality |
26.1% |
26.2% |
| Hazard ratio for death |
0.94 |
Reference |
| Statistical significance |
Not significant |
Reference |
| Death or hospitalization at 12 months |
47.3% |
49.3% |
| Trial population |
1,430 |
1,429 |
The primary endpoint was all-cause mortality. The hazard ratio was 0.94, with a 95% confidence interval of 0.84 to 1.07 and a p-value of 0.59. The composite of death or hospitalization also did not differ significantly between treatment groups.
The trial was published in the Journal of the American Medical Association in 2023. It weakened the investment case for a broad torsemide conversion strategy based on superior survival or reduced hospitalization. Torsemide remains a reasonable alternative when clinicians value its pharmacokinetic characteristics or when a patient has inadequate response to furosemide (Mentz et al., 2023).
What other clinical evidence supports torsemide?
Earlier studies and pharmacology reviews have reported several differences between torsemide and furosemide:
- Torsemide has generally more predictable oral bioavailability.
- Torsemide has a longer duration of action.
- Torsemide may produce a more consistent diuretic effect in patients with gut edema.
- Torsemide has been studied for potential effects on myocardial fibrosis and neurohormonal activation, but these findings have not translated into a confirmed mortality benefit.
- Dose conversion between torsemide and furosemide is approximate and must be adjusted clinically.
Small studies, observational analyses and mechanistic research have generated mixed results. The randomized evidence carries greater weight for treatment selection. TRANSFORM-HF did not support torsemide as a disease-modifying therapy in heart failure.
Are new torsemide clinical trials recruiting?
The major comparative outcomes trial, TRANSFORM-HF, is completed. Its results are the principal recent randomized evidence affecting torsemide’s market position.
Current research interest is more likely to center on:
- Diuretic resistance in acute or advanced heart failure.
- Outpatient volume-management strategies.
- Remote monitoring and titration of loop diuretics.
- Chronic kidney disease and cardiorenal syndrome.
- Comparisons of oral diuretic regimens rather than torsemide monotherapy.
- Combination treatment with agents such as sodium-glucose cotransporter-2 inhibitors or acetazolamide.
Torsemide is often included as a background therapy in heart-failure studies, but that does not create a new torsemide-specific commercial indication. The strongest recent heart-failure development activity has shifted toward SGLT2 inhibitors, mineralocorticoid receptor antagonists, glucagon-like peptide-1 therapies in selected populations, and acute decongestion combinations.
What patents protect torsemide?
Torsemide has no meaningful composition-of-matter exclusivity remaining in the United States. The active ingredient has been marketed for decades, and generic products are widely available.
| Patent and exclusivity category |
Current commercial assessment |
| Composition-of-matter patent |
Expired |
| Basic oral tablet patents |
Expired or commercially nonblocking |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
No current material protection |
| Orphan-drug exclusivity |
Not applicable to the established product |
| Formulation patents |
Limited practical relevance for standard tablets |
| Method-of-use patents |
No widely recognized blocking protection for ordinary approved uses |
| FDA Orange Book strategy |
Generic ANDA competition dominates |
The Orange Book is relevant mainly for identifying patents listed against specific branded torsemide products. Standard generic torsemide tablets are not protected by a current composition patent. A new product using a differentiated formulation, delivery system or combination would require its own patent estate and FDA approval strategy.
What formulations are protected by torsemide patents?
The commercial torsemide market is concentrated in immediate-release tablets. There is no established high-value extended-release or complex-delivery platform comparable to long-acting injectable or depot products.
Potential patentable areas include:
- Modified-release tablets.
- Liquid formulations for patients unable to swallow tablets.
- Fixed-dose combinations with antihypertensive or heart-failure agents.
- Formulations designed for improved absorption in intestinal edema.
- Dose-titration systems for outpatient volume management.
These products would face a high reimbursement hurdle because low-cost generic tablets are available. A formulation patent alone would likely have limited value unless it produces a measurable reduction in hospitalizations, improves adherence or solves a defined administration problem.
When does torsemide lose exclusivity?
Torsemide already lost U.S. market exclusivity. Generic competition is established, and the product is no longer in a conventional brand-to-generic transition.
The relevant commercial timeline is:
| Period |
Event |
| 1980s |
Torsemide enters international and U.S. clinical use |
| 1990s |
U.S. branded Demadex market develops |
| Late 1990s onward |
Generic torsemide competition expands |
| 2010s |
Multiple generic suppliers support broad substitution |
| 2020s |
Soaanz remains a branded option, while generic tablets dominate |
| Current |
Market is mature and largely off-patent |
Generic manufacturers generally do not need to wait for a future basic patent expiry to enter the torsemide tablet market. Entry risk is therefore driven by manufacturing economics, FDA approval, supply contracts and reimbursement rather than patent timing.
What is the Paragraph IV challenge risk for torsemide?
Paragraph IV litigation risk is low for the established immediate-release tablet market because the central torsemide patents have expired or are no longer commercially blocking.
A Paragraph IV filing could arise if a sponsor develops:
- A new extended-release formulation.
- A new indication supported by a method-of-use patent.
- A branded combination product.
- A device-assisted or liquid delivery product.
- A formulation with a patent listed in the Orange Book.
For the ordinary generic tablet, ANDA approval and product quality are more important than patent litigation. Any new patent claim would need to withstand obviousness attacks based on the long history of loop-diuretic formulation and dosing technology.
Which companies compete in the torsemide market?
The market includes generic pharmaceutical companies and a small branded segment.
Generic manufacturers
Depending on product strength, supply period and market channel, torsemide has been marketed by companies such as:
- Teva Pharmaceuticals.
- Amneal Pharmaceuticals.
- Lupin.
- Zydus Pharmaceuticals.
- Apotex.
- Rising Pharma.
- Major contract and private-label suppliers.
The exact supplier mix changes as manufacturers enter or discontinue products. Generic purchasing is concentrated among wholesalers, hospital systems, group purchasing organizations and retail pharmacy chains.
Branded manufacturer
Soaanz is the principal U.S. branded torsemide product in current commercial discussions. Its differentiation is primarily positioning, dosage presentation and brand support rather than a new active ingredient.
Because generic torsemide is available at materially lower cost, the branded product must rely on prescribing preference, payer coverage, physician familiarity or a specific patient-management rationale.
How does torsemide compare with furosemide?
| Attribute |
Torsemide |
Furosemide |
| Generic availability |
Extensive |
Extensive |
| Typical dosing |
Once daily |
Often once or twice daily |
| Oral absorption |
Generally more predictable |
More variable |
| Duration of action |
Longer |
Shorter |
| Clinical outcomes |
No proven mortality advantage |
Reference standard |
| Hospital formulary position |
Alternative or selected use |
Usually first-line loop diuretic |
| Cost |
Low generic cost |
Very low generic cost |
| Heart-failure evidence |
TRANSFORM-HF neutral |
TRANSFORM-HF reference comparator |
| Main commercial advantage |
Pharmacokinetic consistency |
Price, familiarity and broad use |
Furosemide remains the dominant comparator because it is inexpensive, familiar and available in oral and intravenous forms. Torsemide may be selected when clinicians want a longer-acting oral loop diuretic or when response to furosemide is inadequate.
What is the torsemide market size and forecast?
Public company reporting generally does not disclose torsemide revenue separately. The market is therefore best assessed through prescription volume, generic pricing, branded share and hospital utilization rather than a single audited global revenue figure.
Market structure
The U.S. market has the following characteristics:
- High generic penetration.
- Low average selling prices.
- Limited brand growth potential.
- Stable chronic use in heart failure, hypertension and edema.
- Recurrent demand from hospital discharge and outpatient maintenance treatment.
- Limited pricing power for most suppliers.
- Supply-chain sensitivity because several manufacturers compete on narrow margins.
Five-year market projection
A reasonable base case is a low-growth or declining-value market in the United States, with prescription volume broadly stable and nominal revenue pressured by generic price competition.
| Scenario, 2025-2029 |
Volume trend |
Revenue trend |
Principal driver |
| Base case |
0% to 2% annual growth |
-2% to 0% annual change |
Stable demand and continued price erosion |
| Upside case |
2% to 4% annual growth |
0% to 3% annual change |
Greater use in outpatient heart-failure management |
| Downside case |
-1% to -3% annual decline |
-5% to -8% annual change |
Further price compression and substitution by other regimens |
Volume could benefit from an aging population and increasing heart-failure prevalence. Revenue growth will remain constrained because torsemide has no meaningful patent exclusivity and no demonstrated superiority in major outcomes. Any branded expansion would require evidence of improved adherence, fewer admissions or better management of diuretic resistance.
International markets may show higher unit growth because of expanding access to cardiovascular medicines, but local pricing, reimbursement and procurement systems will limit revenue capture.
What manufacturing and intellectual-property barriers affect torsemide?
Manufacturing barriers are moderate rather than high. Torsemide is a small-molecule active pharmaceutical ingredient used in conventional tablets. The key barriers are:
- Reliable API sourcing.
- Control of impurities and degradation products.
- Consistent dissolution and content uniformity.
- FDA current good manufacturing practice compliance.
- Bioequivalence testing.
- Stable supply at low generic prices.
- Contract manufacturing capacity.
The product does not require biologic comparability, cold-chain distribution or complex device manufacturing. This keeps entry barriers below those for biologics, inhaled products and long-acting injectables.
What generic entry risks exist for branded torsemide?
Branded torsemide faces persistent generic substitution risk. The principal risks are:
- Automatic pharmacy substitution where state law and payer policy permit it.
- Low generic acquisition cost.
- Formulary preference for inexpensive loop diuretics.
- Neutral comparative-outcomes data from TRANSFORM-HF.
- Limited differentiation in standard tablet presentation.
- Low switching costs for prescribers and patients.
A branded product could defend share through a differentiated formulation or evidence-based adherence program, but those strategies would face reimbursement pressure.
What litigation and settlement agreements affect torsemide?
There is no major active U.S. patent litigation campaign comparable to the litigation surrounding protected oncology, immunology or specialty medicines. Standard torsemide tablet products are mature generic products, and settlement agreements are not a central market feature.
Any future litigation would more likely involve:
- A new branded formulation.
- Manufacturing patents.
- ANDA certification against a newly listed Orange Book patent.
- Product liability or quality claims.
- Supply and contract disputes.
Key Takeaways
- Torsemide is an established, off-patent loop diuretic with extensive generic competition.
- TRANSFORM-HF found no significant mortality or hospitalization advantage over furosemide.
- The drug remains clinically useful because of once-daily dosing, longer action and more predictable oral absorption.
- The U.S. market is mature, low priced and dominated by generic manufacturers.
- Soaanz is the main branded commercial option, but its differentiation is limited against inexpensive generic tablets.
- Paragraph IV and patent litigation risk is low for conventional immediate-release torsemide.
- A new formulation or combination could create exclusivity, but it would need clear clinical or adherence value to overcome generic pricing.
- The five-year market outlook is stable in volume and flat to declining in nominal revenue under the base case.
FAQs
Is torsemide stronger than furosemide?
Torsemide is often considered more predictable orally and longer acting, but TRANSFORM-HF did not show superior survival or hospitalization outcomes.
Is torsemide FDA approved for heart failure?
Yes. Torsemide is approved for edema associated with congestive heart failure. It is used to manage fluid retention, not to replace disease-modifying heart-failure therapies.
Does torsemide have patent protection in the United States?
The established active ingredient and standard tablet products are off patent. New formulation or combination products could have separate patents.
Can a generic company still file a Paragraph IV certification for torsemide?
Yes, if an ANDA applicant seeks approval for a product covered by a valid, listed patent. For ordinary immediate-release torsemide tablets, the practical patent barrier is low.
Is torsemide a growth pharmaceutical market?
It is primarily a stable-volume generic market. Population aging may support prescription demand, but price erosion and the absence of meaningful exclusivity limit revenue growth.
References
-
DailyMed. (2024). Torsemide tablet prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (2024a). Torsemide: FDA-approved prescribing information. https://www.accessdata.fda.gov/
-
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
ClinicalTrials.gov. (2023). Pragmatic randomized trial of personalized treatment with oral diuretic strategies for hospitalized patients with heart failure: TRANSFORM-HF, NCT03296813. U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT03296813
-
Mentz, R. J., Anstrom, K. J., Eisenstein, E. L., et al. (2023). Effect of torsemide vs furosemide after discharge on survival among patients hospitalized with heart failure: The TRANSFORM-HF randomized clinical trial. JAMA, 329(3), 214-223. https://doi.org/10.1001/jama.2022.23924
